Cue Biopharma (CUE) Net Cash Flow (2017 - 2025)

Cue Biopharma has disclosed Net Cash Flow across 9 years of filings, most recently posting $15.4 million for Q4 2025.

• Net Cash Flow for Q4 2025 came in at $15.4 million, up 254.96% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.7 million (up 117.96% YoY), and the FY2025 annual result was $4.7 million, up 117.96% from the prior year.
• Net Cash Flow came in at $15.4 million for Q4 2025 at Cue Biopharma, up from -$15.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $21.9 million in Q4 2022 to a low of -$36.4 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$2.5 million (2021), against an average of -$2.4 million.
• Across the five-year window, Net Cash Flow jumped 770.93% in 2022 and tumbled 760.16% in 2025, its largest moves.
• Cue Biopharma's Net Cash Flow stood at -$3.3 million in 2021, then surged by 770.93% to $21.9 million in 2022, then sank by 128.22% to -$6.2 million in 2023, then tumbled by 61.29% to -$10.0 million in 2024, then jumped by 254.96% to $15.4 million in 2025.
• The last three Net Cash Flow figures came in at $15.4 million (Q4 2025), -$15.8 million (Q3 2025), and $14.4 million (Q2 2025), per Business Quant data.